S-Adenosylhomocysteine

S-Adenosylhomocysteine

SCHEMBL16087786

Nc1ncnc2c1ncn2C1O[C@H](CSCC[C@H](N)C(=O)O)[C@@H](O)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DOT1L Q8TEK3 9/20 1.00
▸ DNMT1 P26358 7/20 1.00
▸ DNMT3B Q9UBC3 6/20 1.00
▸ EZH2 Q15910 4/20 1.00
▸ CARM1 Q86X55 2/20 1.00
▸ EHMT2 Q96KQ7 2/20 1.00
▸ PRMT1 Q99873 2/20 1.00
▸ NNMT P40261 2/20 1.00
▸ TRDMT1 O14717 1/20 1.00
▸ PRMT5 O14744 1/20 1.00
▸ SUV39H1 O43463 1/20 1.00
▸ PRMT3 O60678 1/20 1.00
▸ INMT O95050 1/20 1.00
▸ NSD2 O96028 1/20 1.00
▸ PNMT P11086 1/20 1.00
▸ HNMT P50135 1/20 1.00
▸ WDR5 P61964 1/20 1.00
▸ KMT2A Q03164 1/20 1.00
▸ SETDB1 Q15047 1/20 1.00
▸ RBBP5 Q15291 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
S-Adenosylhomocysteine SCHEMBL12378912 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL12436336 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL18296901 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL10871157 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL17087726 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL17316162 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL14411397 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL804238 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL21160481 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1
S-Adenosylhomocysteine SCHEMBL14434697 1.00 DOT1L (1.00) DOT1LDNMT1DNMT3BEZH2CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334527-B2 Inhibitors of human EZH2, and methods of use thereof Epizyme, Inc. (US) 2016-05-10 — — US disclosed
US-9334527-B2 Inhibitors of human EZH2, and methods of use thereof Epizyme, Inc. (US) 2016-05-10 — — US disclosed
US-20140275081-A1 INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF Epizyme, Inc. (US) 2014-09-18 — — US disclosed
US-20140275081-A1 INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF Epizyme, Inc. (US) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275081-A1 INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF EZH2, DOT1L, PRDM7 DOT1L 2/4885DNMT1 29/4885DNMT3B 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback